Amgen (AMGN) tops profit expectations, revenue rises 5%
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Citi initiates UiPath coverage with Buy rating and $23 target
- Trump says Canada's Bombardier must build jets in US or lose market access
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- European shares subdued as surging crude sharpens focus on ECB rate path
- S&P 500, Dow set to open lower as Gulf tensions send oil to over six-week high
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Amgen sales rise, but shares off as investors await obesity data
October 31, 2023 7:10 AM EDTBy Deena Beasley
(Reuters) -Amgen on Tuesday said third-quarter sales rose 5%, but a full-year sales forecast raise only reflected additional revenue from its $27.8 billion acquisition this month of Horizon Therapeutics and its shares fell nearly 4%.
Sales of some high profile medicines also fell short of expectations, likely contributing to the share move.
Amgen said it expects to announce findings from an early-stage trial of experimental obesity pill AMG786 in the first half of next year, and to have results from a mid-stage trial of a different, injected obesity candidate, AMG133, by late next year.
"Overall... More
Amgen (AMGN) Tops Q3 EPS by 28c; Raises Outlook
October 31, 2023 7:03 AM EDTAmgen (NASDAQ: AMGN) reported Q3 EPS of $4.96, $0.28 better than the analyst estimate of $4.68. Revenue for the quarter came in at $6.9 billion versus the consensus estimate of $6.92 billion.
GUIDANCE:
Amgen sees FY2023 EPS of $18.20-$18.80, versus the consensus of $17.31. Amgen sees... More
Amgen (AMGN) PT Raised to $272 at UBS
October 30, 2023 9:21 AM EDTUBS analyst Colin Bristow raised the price target on Amgen (NASDAQ: AMGN) to $272.00 (from $260.00) while maintaining a Neutral rating.... More
